<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03975049</url>
  </required_header>
  <id_info>
    <org_study_id>SAHMO201</org_study_id>
    <nct_id>NCT03975049</nct_id>
  </id_info>
  <brief_title>Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer</brief_title>
  <official_title>A Prospectively Randomized Phase III Trial Comparing Short-term mFOLFOXIRI, Long-term mFOLFOX6 and Traditional Chemoradiation as Preoperative Neoadjuvant Therapy for Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sixth Affiliated Hospital, Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preoperative radiation with single agent chemotherapy as sensitizer is the standard care of&#xD;
      locally advanced rectal cancer.&#xD;
&#xD;
      Local irradiation significantly increases surgical complications and impairs quality of life.&#xD;
&#xD;
      Combination chemotherapy alone seems promising and provides similar benefit to chemoradiation&#xD;
      as neoadjuvant therapy.&#xD;
&#xD;
      Early administration of systemic therapy is also proved beneficial for long-term survival.&#xD;
&#xD;
      The purpose of this study is to compare the efficacy of chemotherapy alone with short-term&#xD;
      modified FOLFOXIRI or long-term mFOLFOX with standard chemoradiation as neoadjuvant therapy&#xD;
      for locally advanced rectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with cT3-4 or cN+ and cM0 by pelvic MR and chest + abdominal CT scan will be&#xD;
      randomized to the following three groups:&#xD;
&#xD;
      Group A: Traditional chemoradiation.&#xD;
&#xD;
      Fluorouracil 225 mg/m2/day continuous intravenous infusion on weekdays for five weeks; local&#xD;
      irradiation 2GY/day on weekdays, totally 50GY.&#xD;
&#xD;
      At the end of chemoradiation, patients will receive an evaluation with MR and CT scan.&#xD;
&#xD;
      If the efficacy is defined as CR, PR or SD, the TME will be performed in 6-8 weeks since the&#xD;
      last irradiation.&#xD;
&#xD;
      If the disease progress with the possibility of R0 resection, the operation will be given&#xD;
      soon.&#xD;
&#xD;
      If the tumor progress to impossible for R0 resection, the salvage chemotherapy will be given&#xD;
      accordingly.&#xD;
&#xD;
      Adjuvant chemotherapy of 6-8 cycles of mFOLFOX will be administered 3-4 weeks after R0&#xD;
      resection.&#xD;
&#xD;
      Group B: Short-term mFOLFOXIRI.&#xD;
&#xD;
      Oxaliplatin 85 mg/m2 on day 1; irinotecan 150 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1;&#xD;
      fluorouracil 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days; prophylactic&#xD;
      G-CSF support is recommended.&#xD;
&#xD;
      Patients are planned to receive 4 cycles of mFOLFOXIRI regimen preoperatively and&#xD;
      postoperatively, respectively.&#xD;
&#xD;
      Before operation, efficacy evaluations will be performed every two cycles by CT and MR scan.&#xD;
&#xD;
      If the evaluation is defined as no progression without severe toxicity, the next 2 cycles&#xD;
      will be given.&#xD;
&#xD;
      If the primary lesion progress without distant metastasis, patients will be assigned to group&#xD;
      A.&#xD;
&#xD;
      If distant metastasis occurr during chemotherapy, patients will withdraw from the trial and&#xD;
      be treated further at the discretion of attending physicians.&#xD;
&#xD;
      Postoperative chemotherapy will initiate 3-4 weeks after R0 resection.&#xD;
&#xD;
      Group C: Long-term mFOLFOX.&#xD;
&#xD;
      Oxaliplatin 85 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 400 mg/m2 bolus&#xD;
      and 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days.&#xD;
&#xD;
      Patients are planned to receive 8-9 cycles of mFOLFOX regimen preoperatively and 3-4 cycles&#xD;
      postoperatively.&#xD;
&#xD;
      Efficacy evaluations will be performed every three cycles by CT and MR scan before TME.&#xD;
&#xD;
      If the evaluation is defined as no progression without severe toxicity, the next 3 cycles of&#xD;
      mFOLFOX will be given with the maximum of 9 cyces.&#xD;
&#xD;
      If the primary lesion progress without distant metastasis, patients will be assigned to group&#xD;
      A.&#xD;
&#xD;
      If distant metastasis occurr during chemotherapy, patients will withdraw from the trial and&#xD;
      be treated further at the discretion of attending physicians.&#xD;
&#xD;
      Postoperative chemotherapy will initiate 3-4 weeks after R0 resection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">July 2029</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>The interval from randomization to local recurrence, distant metastasis, death or the last follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>The interval from randomization to local recurrence, death or the last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>The interval from randomization to distant metastasis, death or the last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical complication</measure>
    <time_frame>3 years</time_frame>
    <description>Surgical complication including anastomotic leakage, anastomotic stricture, intestinal obstruction, postoperative pelvic bleeding and poor wound healing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related quality of life</measure>
    <time_frame>up to 3 years</time_frame>
    <description>EORTC QOL questionaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Tumor regression grade after neoadjuvant therapy</measure>
    <time_frame>3 months</time_frame>
    <description>According to pathological slides</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">933</enrollment>
  <condition>Rectal Cancer</condition>
  <condition>Chemotherapy Effect</condition>
  <arm_group>
    <arm_group_label>5-Fu + RT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5Fu + RT for five weeks --- 6-8 weeks of interval --- TME --- mFOLFOX * 6-8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mFOLFOXIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mFOLFOXIRI * 4 --- TME --- mFOLFOXIRI * 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mFOLFOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mFOLFOX * 9 --- TME --- mFOLFOX * 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Chemoradiation</intervention_name>
    <description>Fluorouracil 225 mg/m2/day continuous intravenous infusion on weekdays for five weeks; local irradiation 2GY/day on weekdays, totally 50GY.</description>
    <arm_group_label>5-Fu + RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOXIRI Protocol</intervention_name>
    <description>Oxaliplatin 85 mg/m2 on day 1; irinotecan 150 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days; prophylactic G-CSF support is recommended.</description>
    <arm_group_label>mFOLFOXIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folfox Protocol</intervention_name>
    <description>Oxaliplatin 85 mg/m2 on day 1; leucovorin 400 mg/m2 on day 1; fluorouracil 400 mg/m2 bolus and 2400 mg/m2 civ over 46h; treatment will be repeated every 14 days.</description>
    <arm_group_label>mFOLFOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1）Age: 18 to 75 years old;&#xD;
&#xD;
          -  2）Histological diagnosis of rectal adenocarcinoma;&#xD;
&#xD;
          -  3）Distance form anal margin ≤ 12cm: cT3-4 or cN+ and cM0 by pelvic MR and chest +&#xD;
             abdominal CT, estimated possible for R0 resection;&#xD;
&#xD;
          -  4）There is no signs of intestinal obstruction, or obstruction of intestinal after&#xD;
             treating with proximal colostomy has been relieved;&#xD;
&#xD;
          -  5）Patients did not previously receive rectal surgery, chemotherapy or radiation&#xD;
             therapy , biological treatment , except for endocrine therapy;&#xD;
&#xD;
          -  6）ECOG Performance Status :0-1&#xD;
&#xD;
          -  7）Life expectancy: more than 3 years;&#xD;
&#xD;
          -  8）sufficient bone marrow, liver and kidney function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1）Arrhythmia requires treatment with antiarrhythmia (except for beta-blockers or&#xD;
             digoxin), symptomatic coronary artery disease, myocardial ischemia (myocardial&#xD;
             infarction within the last 6 months) or congestive heart failure exceeding NYHA class&#xD;
             II;&#xD;
&#xD;
          -  2）Severe hypertension with poor control;&#xD;
&#xD;
          -  3）History of HIV infection or active phase of chronic hepatitis B or C infection with&#xD;
             high copy viral DNA;&#xD;
&#xD;
          -  4）Other active serious infections according to NCI-CTC version 4.0;&#xD;
&#xD;
          -  5）There is preoperative evidence for distant metastasis outside pelvis;&#xD;
&#xD;
          -  6）Cachexia and organ function decompensation&#xD;
&#xD;
          -  7）History of pelvic or abdominal radiotherapy;&#xD;
&#xD;
          -  8）Multiple primary cancer;&#xD;
&#xD;
          -  9）Patients with epilepcy requiring treatment ( steroids or antiepileptic treatment);&#xD;
&#xD;
          -  10）History of other malignant tumors within 5 years, except for cured cervical&#xD;
             carcinoma in situ or skin basal cell carcinoma;&#xD;
&#xD;
          -  11）Drug abuse and medical, psychological or social conditions interfering patient&#xD;
             participation in research or the evaluation of research results;&#xD;
&#xD;
          -  12）Any allergy to clinical research drugs or any drugs associated with this study;&#xD;
&#xD;
          -  13）Any unstable condition or condition that may endanger safety and compliance of&#xD;
             patients;&#xD;
&#xD;
          -  14）Pregnancy or the lactating female without adequate contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ping Lan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sixth Affiliated Hospital, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ping Lan, MD</last_name>
    <phone>86-20-38285497</phone>
    <email>lanping@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jian Xiao, MD</last_name>
    <phone>86-20-38285497</phone>
    <email>xiaoj26@mail.sysu.edu.cn</email>
  </overall_contact_backup>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>June 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2019</study_first_posted>
  <last_update_submitted>June 2, 2019</last_update_submitted>
  <last_update_submitted_qc>June 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

